What the companies actually say, word for word
These are quotations, not summaries, read from the companies' own sites on 27 August 2026.
Company pages change. Everything below was read directly from the company's own website on 27 August 2026 and is quoted exactly. Check the sites yourself before you decide anything.
LifeView, from Genomic Prediction: Unlike any other service in the world, LifeView patients also have access to Embryo Health Scores, which have been proven to reduce the risk of common diseases such as diabetes, cancer, and heart disease in your embryo.
The word doing the work in that sentence is proven, and it is the company's own word. The same site also states: At this time, our tests are not covered by insurance.
Orchid Health: Have healthy babies
and Mitigate more risks with the world's most advanced whole genome screening for embryos during IVF.
Nucleus Genomics: Have your best baby with our all-in-one IVF experience.
Most couples only wonder. Now you can choose.
Go beyond the standard with height, IQ and more.
See the predicted eye color, height, and even intelligence.
Now set those beside what the American Society for Reproductive Medicine wrote in the opinion it released in December 2025. On selecting for traits: PGT-P used for trait selection (e.g., height, intelligence, eye color) is not within the scope of reproductive medicine and will not be addressed in this document.
On the promise itself: No technology can guarantee healthy offspring.
And on exactly this gap: Without comprehensive data, there is a risk that patients could be misled, intentionally or unintentionally, into believing that PGT-P offers guarantees or reliable protection against complex diseases, when in fact the technology is still in an early stage of development.
This is not new. In 2021 the New England Journal of Medicine described what was already on offer: Genomic Prediction currently offers ESPS to screen for type 1 and type 2 diabetes; breast, prostate, and testicular cancer; malignant melanoma; coronary artery disease; hypercholesterolemia; hypertension; and schizophrenia. As recently as December 2020, the company also advertised ESPS for idiopathic short stature and intellectual disability.
That was a description of 2021, and it is quoted here as one.
The American College of Medical Genetics and Genomics has one sentence on selling this sort of testing straight to the public: The ACMG is of the opinion that prenatal testing for disorders that exhibit multigenic or polygenic inheritance is not yet appropriate for clinical use and should not be offered as direct-to-consumer testing.
"Is this being sold to me as a medical test or as a consumer product?"
"Which professional society recommends this?"